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Background: Phosphatidylserine (PS) is a phospholipid normally located in the inner leaflet of the cell membrane.
PS is translocated from the inner to the outer leaflet of the plasma membrane during the early stages of apoptosis
and in necrosis. In cell and animal studies, reversible PS externalisation to the outer membrane leaflet has been
observed in viable cells. Hence, PS markers have been proposed as markers of both reversibly and irreversibly
damaged cells. The purpose of this experimental study in pigs was to investigate the kinetics of the newly
introduced PS marker technetium-99m-labelled lactadherin (99mTc-lactadherin) in comparison with the well-known
PS tracer 99mTc-annexin V with special reference to the renal handling of the tracers. The effective dose for humans
was estimated from the biodistribution in 24 mice.
Methods: Nine anaesthetised pigs randomly allocated into two treatment groups were administered a single
injection of either 99mTc-lactadherin or 99mTc-annexin V. Renal perfusion was assessed by simultaneous injection of
51Cr-EDTA. Throughout the examinations, planar, dynamic scintigraphy of the trunk was performed, urine was
collected and arterial and renal vein blood was sampled. The effective dose was estimated using the adult male
phantom from the RADAR website.
Results: 99mTc-lactadherin was cleared four times faster from plasma than 99mTc-annexin V, 57 ± 13 ml/min (mean ± SD)
versus 14 ± 2 ml/min. 99mTc-lactadherin had a predominant uptake in the liver, whereas 99mTc-annexin V was
primarily taken up by the kidneys. The estimated effective human dose after single injection of 99mTc-lactadherin
and 99mTc-annexin V was 5.8 and 11 μSv/MBq, respectively.
Conclusions: The high hepatic uptake of 99mTc-lactadherin compromises the use of 99mTc-lactadherin for imaging
PS externalisation in the liver. Due to scatter from the liver, the use of in vivo visualisation of PS externalisation in
the lower thorax and upper abdomen by 99mTc-lactadherin is challenged, but not precluded. In contrast to
99mTc-annexin, 99mTc-lactadherin has a low renal uptake and may be the preferred tracer for imaging PS
externalisation in the kidneys. The effective dose after injection of 99mTc-lactadherin and 99mTc-annexin was low.
Recommendations regarding the clinical use of 99mTc-lactadherin must await tracer kinetic studies in patients.
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Phosphatidylserine (PS) is a phospholipid normally located
in the inner leaflet of the cell membrane. PS is translocated
from the inner to the outer leaflet of the plasma membrane
during the early stages of apoptosis and in necrosis [1,2].
In cell and animal studies, reversible PS externalisation to
the outer membrane leaflet has been observed in viable
cells [3-5]. Hence, PS markers have been proposed
as indicators of damaged cells, whether reversibly or
irreversibly injured [6-8].
Fluorescent or radio isotope-labelled annexin V is fre-
quently used to visualise the externalisation of PS on the
cell surface [4,9,10]. Recently, the glycoprotein lactadherin
(also known as MFG-E8) was introduced as a more sensi-
tive PS marker [11,12], and the technetium-99m-labelled
lactadherin (99mTc-lactadherin) has been proven to readily
visualise PS externalisation on cells [13].
The binding affinity of annexin V and lactadherin to cells
with decreasing transmembrane potential is increased [14].
Since the membrane of apoptotic, hypoxic and ischemic
cells depolarised, annexin V and lactadherin most likely
bind to these cells with a higher affinity than to cells with
preserved membrane potential.
The PS externalisation on dying cells is described as an
‘eat me’ signal to the macrophages that mediate engulfment
[15]. Lactadherin facilitates this phagocytosis by acting as a
bridge between exposed PS and the αvβ3 integrin on the
macrophage surface [16]. It is well known that the
inflammatory response to cell death is minimised
when dying cells are effectively removed. A more
direct anti-inflammatory effect of lactadherin has been
demonstrated ex vivo by Voll et al. [17]. They showed that
lactadherin increases the secession of anti-inflammatory
cytokines from the macrophage. In experimental studies
of inflamed and ischemic tissues, lactadherin is described
as an organ-protecting component [18-20].
Given the promising future of lactadherin, both in diag-
nostic imaging and for anti-inflammatory treatment, know-
ledge of the kinetics of the compound is highly relevant.
The purpose of the present pharmacokinetic study in
pigs was to compare the kinetics of 99mTc-lactadherin
with that of 99mTc-annexin V with special reference to
the renal handling. Further, the aim was to estimate an
effective human dose by the use of data from an earlier
biodistribution study in mice [21].
Methods
Animal preparation and experimental protocol
The study was approved by the Danish Inspectorate of
Animal Experimentation and performed in accordance
with their guidelines.
Nine female Danish Landrace/Yorkshire pigs, weighing
20 kg, were premedicated with midazolam 3 mg/kg
(DormicumW, Roche, Basel, Switzerland) and s-ketamine(S-Ketamin, Pfizer Aps, Ballerup, Denmark) subcutane-
ously. Subsequently, the pigs received a 375 mg bolus of
pentobarbital (MebumalW, DAK, Copenhagen, Denmark)
in an auricular vein and were intubated and ventilated
(Datex Ohmeda s/5 Avance ventilator, GE Healthcare,
Little Chalfront, UK). During the entire data collection,
anaesthesia was maintained by sevoflurane (Sevorane
100%, Abbotte Scandinavia AB, Solna, Sweden).
The arterial blood gases, pH, blood glucose and electro-
lytes were frequently monitored (ABL, Radiometer A/S,
Brønshøj, Denmark), and ventilation was adjusted to keep
the blood gases in physiological ranges. An intravenous
saline infusion was maintained at a rate of approximately
200 ml · h−1. Temperature was registered with a rectal
probe and was kept between 38°C and 39°C, which is the
physiological range of temperature for pigs of this size. An
appropriate environmental temperature was applied during
transportation from the farm and during the study. If
necessary, blankets and/or fans were used to maintain a
steady, physiologic temperature.
A kidney vein catheter for venous blood samples was
inserted through a sheath in the femoral vein. Since kid-
ney vein blood has a higher oxygenation than mixed
venous blood, the position of the catheter was assured
by comparing the oxygen saturation in the kidney and
jugular vein blood drawn simultaneously. Blood samples
were drawn slowly from the kidney vein catheter to
avoid aspiration of mixed venous blood from the inferior
cava vein.
Arterial blood sampling and blood pressure measurement
were performed through a sheath in the femoral artery.
Heart rate and blood pressure were continuously moni-
tored to ensure hemodynamic stability. A sheath was also
inserted in the right internal jugular vein for tracer admin-
istration and saline infusion. The urinary bladder was
catheterized and the urine collected.
The preparation time from the induction of anaesthesia
to tracer injection was approximately 80 min.
Tracer preparation and administration
The radio synthesis of 99mTc-lactadherin and 99mTc-
annexin V has been described previously [13,21]. Five pigs
received an injection dose (ID) of 19 to 38 MBq 99mTc-
lactadherin (99mTc-hynic-lactadherin, Department of
Nuclear Medicine, Denmark), and four pigs received 25 to
37 MBq 99mTc-annexin V (99mTc-hynic-recombinant
human (rh)-annexin V, Reactionlab A/S, Lynge, Denmark)
bolus in the jugular vein. The effective specific acti-
vity of 99mTc-lactadherin and 99mTc-annexin V at the
time of injection was approximately 3.1 and
3.7 MBq/μg protein, respectively. The radiochemical
purity was over 95% for both tracers. Simultaneously
with PS tracer injection, all nine pigs received an
intravenous dose of 4 MBq 51Cr-EDTA (Behring,
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flow (RPF).
Dynamic scintigraphy
Dynamic imaging (64 × 64 matrix) of the trunk in the
posterior projection was performed with a single-headed
gamma camera (BrightView, Philips Medical, North
Andover, MA, USA) equipped with a LEHR collimator.
During the first 120 s post-injection (pi.), a frame rate of 1
per second was applied. From 2 to 60 min, the frame rate
was 1 per minute, and from 60 min to the end of the study,
1 frame was recorded over 5 min (12 frames per hour).
The biodistribution of the PS tracers was evaluated by
studying the tracer activity over time. Representative
areas of the heart, lungs, liver, spleen and kidneys were
drawn as regions of interest (ROI) on the scintigrams,
and time/activity curves were generated. Activity was
assessed as counts per minute per pixel and corrected
for background radiation measured under the left kidney
and for radioactive decay.
This method provides only a semi-quantitative descrip-
tion of tracer uptake in different organs over time, and the
method is less suitable for quantitative comparison of tracer
uptake between organs. Planar scintigraphy simplifies the
three-dimensional tracer distribution to a two-dimensional
image. Hence, organ activity assessed from planar images is
proportional not only to tracer uptake, but also to the
vertical thickness of the organs and the activity in overlying
and underlying tissues.
Blood and urine sampling
Blood samples (3 ml) were drawn from the renal vein
and the femoral artery 2 min before tracer injection and
at 2, 5, 10, 15, 20, 25, 30, 40, 50, 60, 75, 90, 105, 120, 135
and 150 min and then every 30th minute up to 240 min
pi. Blood from two pigs, one injected with 99mTc-annexin
V and one with 99mTc-lactadherin, were sampled up to
only 150 min pi. Urine was collected simultaneously with
blood sampling.
Radioisotope activity was counted in 1 ml plasma, 1 ml
whole blood and 1 ml urine in a scintillation detector
(Cobra II, Packard, Meriden, CT, USA) to a statistical
accuracy of 1%. 99mTechnetium activity was counted
immediately after the experiment and 51Chromium activity
3 to 10 days later. Correction was made for background
radioactive decay and cross-talk between channels.
Calculations
The calculations were performed in three steps:
1. Whole blood clearance (ClWb), plasma clearance
(ClP), volume of distribution (Vd), urinary clearance
(Clu), renal extraction (Etracer) and fraction of
injected dose (ID) excreted in urine were calculatedfor all three tracers using the data collected from
blood and urine samples.
2. RPF was calculated using the reference tracer
51Cr-EDTA and the equation
ClrEDTA ¼ RPF EEDTA
assuming that Clr-EDTA = urinary clearance (Clu-EDTA).
3. Renal clearance (Clr-tracer) of annexin and lactadherin
was calculated from the equation
Clrtracer ¼ RPF Etracer
The fraction of the tracer retained in the kidneys
was calculated as the relative difference in renal
clearance (Clr-tracer) and urinary clearance (Clu-tracer)
as a fraction of the renal clearance (Clr-tracer).
Step 1
Whole blood and plasma clearances (Cl) were calculated
as the ratio between the dose of the injected tracer (ID)





The area under the time-activity curve was calculated
by fitting the time-activity data from the plasma and blood
samples with three exponential functions using a peeling-
off technique in a computer program (Sigma Plot 11,
Systat Software, Chicago, IL, USA). Three exponential
functions were used to get a satisfactory data fit. We did
not use a compartment model.
Volume of distribution (Vd) was assessed from the
equation: Vd ¼ t  Clp , where t is the mean transit time
and Clp is the plasma clearance of the tracer.
Urinary clearance (Clu) was calculated according to
the equation:




where U denotes the concentration of the tracer in the
urine and V the volume of urine collected. The product of
U and V was divided by the area under the time-activity
curve.
Renal extraction (E) was calculated from the relative
difference in the plasma concentration of arterial blood
(Pa) and renal vein blood (Pv):
E ¼ Pa  Pvð Þ=Pa
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well as an average value corrected to a mean time.
The fraction of ID excreted in urine is the amount of
tracer found in urine divided by the ID.
Step 2
RPF was calculated as follows:
ClrEDTA ¼ RPF EEDTA⇒
RPF ¼ ClrEDTA=EEDTA;
where Clu-EDTA was used as an estimate of Clr-EDTA.
EDTA is excreted solely by glomerular filtration, making
Clu-EDTA a good estimate of Clr-EDTA. Mean RPF was cal-
culated for all nine pigs together and separately for pigs
receiving either 99mTc-annexin or 99mTc-lactadherin.
Step 3
Renal clearance (Clr) was calculated as follows:
Clrtracer ¼ RPF Etracer
Fraction retained in the kidneys was calculated using the
equation:
Clr–Cluð Þ=Clr
Dosimetry calculation on published data
The biodistribution of 99mTc-lactadherin and 99mTc-
annexin V has been studied by our group in 24 mice
sacrificed at 10, 60, or 180 min pi. [21]. From these data
and by the use of the adult male phantom from the
RADAR website (USA), an effective radiation dose to
the human body after a single injection with the

























Figure 1 Mean arterial whole blood concentration (counts per minuteResults
Results derived from blood and urine samples
The whole blood and plasma disappearance curves
of 99mTc-lactadherin, 99mTc-annexin V and 51Cr-EDTA
are shown in Figures 1 and 2, respectively. During the first
15 min after injection, 99mTc-lactadherin and 51Cr-EDTA
concentration decreased almost in parallel, but from the
15th minute pi., the 99mTc-lactadherin concentration
decreased more rapidly than the EDTA concentration.
During the entire study period, the decrease in the
concentration of 99mTc-annexin V was slower than that
for the two other tracers. The main results from the calcu-
lations performed on the data from the blood and urine
samples are listed in Table 1.
The renal extractions of the three tracers are shown in
Figure 3. Mean renal extraction of 99mTc-annexin V was
initially 0.12 but close to zero 120 min pi. The mean renal
extraction of 99mTc-lactadherin was approximately zero
throughout the experiment. EDTA's renal extraction was
0.25 initially, but the fraction gradually decreased to 0.18,
240 min pi.
Scintigrams
The visual distribution of 99mTc-lactadherin was quite
different from the uptake pattern of 99mTc-annexin V
(Figure 4). The 99mTc-annexin V was primarily taken up by
the kidneys, whereas 99mTc-lactadherin was predominately
taken up in the liver.
The organ-specific time/activity curves of 99mTc-
lactadherin and 99mTc-annexin V confirmed the
difference between the two PS tracers' hepatic and
renal uptake (Figure 5). Initially, 99mTc-lactadherin
accumulated rapidly in the liver, but from the 15th minute
pi., the curve equalled out at a plateau approxi-
mately four times the average activity in the trunk,
and 2.2 times the activity of the kidney. During the
first hour pi., 99mTc-annexin V accumulated in the
kidneys before the kidney activity levelled out at a120 180 240
Minutes
99mTc-Lactadherin 51Cr-EDTA































Figure 2 Mean arterial plasma concentration (counts per minute/ml plasma/ID) of the three tracers.
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trunk activity.
Effective dose estimated from biodistribution in mice
The effective dose for 99mTc-lactadherin and for 99mTc-
annexin V was estimated from previously published
data [21]. The biodistribution of 99mTc-lactadherin in
mice was found to be 64% in the liver, 4.7% in the
kidneys, 12% in the blood and 19% in the remaining
body. Effective residence times (worst case values)
were estimated as 6, 6, 3.3 and 20 h, respectively.
This biodistribution is assumed to be representative
for humans, and by using dose factors from the adult
male phantom from the RADAR website, the effect-
ive dose was estimated to be 5.8 μSv/MBq. The
biodistribution of 99mTc-annexin V was found to be
48% in the kidneys, 12% in the liver, 12% in the
blood and 28% in the remaining body. Effective resi-
dence times (worst case values) were estimated as 6,
6, 4.4 and 18.6 h, respectively. The effective dose was
calculated as 8.8 μSv/MBq.Table 1 Results derived from blood and urine samples
Lactadherin
Plasma clearance (ml/min) 57 ± 13
Volume of distribution (L) 8.2 ± 3.6
Urinary clearance (ml/min) 2.4 ± 1.3
Renal extraction fraction 0.011 ± 0.004
Fraction of ID excreted in urine (120/180/240) 0.016/0.019/0
Urinary flow (ml/min) 1.7 ± 0.8
Renal plasma flow (ml/min) 152 ± 62
Renal clearance (ml/min) 1.6 ± 0.9
Fraction retained in kidneys −1.10 ± 1.3
Data were calculated from blood and urine samples and presented as mean ± SD. R
120, 180 and 240 min after injection of tracer. Fractions retained in kidney were cal
kidneys. ID, injected dose; n, number.Discussion
The tracer kinetics of 99mTc-annexin V has been studied
in animal models as well as in humans. Clinical studies
have shown the ability of 99mTc-annexin V to visualise
apoptosis, e.g. the complete or partial tumour response
was associated with increased uptake of 99mTc-annexin
V [22-24].
99mTc-lactadherin is a newer tracer with a higher affinity
for the PS than 99mTc-annexin V. Tracer kinetic studies
have been performed only in vitro and in small animals
[13,21]. We have made a comparative study of the kinetics
of 99mTc-lactadherin and 99mTc-annexin V in pigs, an ani-
mal close to man both regarding the heart and the kidneys.
The present study showed important differences in the
kinetics of 99mTc-lactadherin and 99mTc-annexin V. The
renal extraction of 99mTc-annexin V was only 3.7%, but
80% was retained in the kidneys and the kidneys were
clearly delineated on the scintigrams. The renal clea-
rance of 99mTc-annexin V comprises nearly one third of
the plasma clearance. Previous studies have also demon-
strated that 99mTc-annexin V was predominantly taken(n = 5) Annexin (n = 4) EDTA (n = 9)
14 ± 1.9 42 ± 6.8
3.3 ± 0.35 6.3 ± 1.2
1.0 ± 0.37 28 ± 8.07
0.037 ± 0.010 0.21 ± 0.05
.055 -/0.023/0.055 0.17/0.47/0.70
2.4 ± 1.4 2.0 ± 1.1
144 ± 22 148 ± 47
5.3 ± 1.5 30 ±6.0
0.80 ± 0.10 0.00
enal extractions were corrected to a mean time. Fraction excreted in urine at



















99mTc-Annexin 99mTc-Lactadherin 51 Crom EDTA
Figure 3 The mean renal plasma extraction fraction of the three tracers.
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take [25]. The reason for the intense kidney accumulation
remains unclear, but the uptake seems to be relatively
nonspecific and does not alter upon apoptosis induction
with cycloheximide in mice [26]. The same authors specu-
late that the reason might be an organ-specific endocytotic
mechanism for annexin V that relies on a non-PS
-dependent membrane association. The kidney uptake
could have been free 99mTc-pertechnetate. However, we
did not see any activity in the thyroid, making this expla-
nation less likely. The vague visualisation of the liver
by 99mTc-annexin V corresponded with previous findings
[25], and it may be due only to the blood background.
A different pattern was observed for 99mTc-lactadherin
for which we observed a high hepatic uptake and only aFigure 4 Scintigrams of two representative pigs. The scintigrams
were obtained from 220 to 240 min after injection of (A)
99mTc-lactadherin and (B) 99mTc-annexin V.minor uptake in the kidneys. The renal extraction of 99mTc-
lactadherin was as low as 1% and the renal clearance
of 99mTc-lactadherin responding to only 2.8% of the
plasma clearance. The rapid and very dominant liver
uptake corresponded well to the rapid plasma clearance
of 99mTc-lactadherin, the latest being more than four times
faster than the plasma clearance of 99mTc-annexin V. The
distribution of the two PS tracers in the present study is in
concordance with the results from the earlier study in
mice [21].
The dominant liver uptake indicated that 99mTc-
lactadherin is either primarily metabolized in or slowly ex-
creted by the liver as we did not observe a decline in the
time/activity curve over the liver. Further, no bile ducts or
bowl activity was visualised on the scintigrams, indicating
that neither the isotope nor the tracer was excreted from
the liver to a significant degree during the study periods.
Lactadherin is a glycoprotein identified in mammary
glands, but also present in the brain, heart, lungs, spleen,
intestines, liver, kidneys, reproductive organs and blood
[27]. Notably, endogenously secretion might in many
cases be ascribed to tissue-embedded macrophages [28].
This is in concordance with the suggested function of
lactadherin, i.e. the glycoprotein operates as a bridging
molecule between PS-exposing apoptotic/necrotic cells
and integrin receptors on macrophages [16,29]. What
hitherto is known about the nature of lactadherin pre-
scribes that it most likely will be found as a membrane-
associated component, especially the ones with high
curvature [30], and suggests that under normal physio-
logical conditions, blood lactadherin will be carried
around on cell debris, membrane fragments or
microvesicle-like structures. The liver has a well-
developed ability to engulf apoptotic cells, involving the
action of hepatocytes, Kupffer and endothelial cells [31].
This may explain the presently observed high and rapid

































Kidneys Heart Lungs Liver Spleen Trunk in total
Figure 5 Time/activity curves from ROIs for different organs from two representative pigs. The curves illustrate the kinetics of
99mTc-lactadherin and 99mTc-annexin V.
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of 99mTc-lactadherin leaves no compound for targeting
PS. However, in an ischemic and reperfused porcine
model, we studied the PS externalisation in the myocar-
dium after reperfusion using 99mTc-lactadherin (RH
Poulsen et al., unpublished work). A well-defined uptake
of 99mTc-lactadherin was found in the part of the myocar-
dium exposed to ischemia and reperfusion, suggesting
sufficient amount of 99mTc-lactadherin for PS targeting
despite the extensive hepatic uptake.
The effective dose for 99mTc-lactadherin and for 99mTc-
annexin V was estimated from previously published data,
assuming that the biodistribution in mice is representative
for humans. The effective human dose after a single injec-
tion of 99mTc-lactadherin was estimated to be 5.8 and
8.8 μSv/MBq for 99mTc-annexin V which is in the clini-
cally acceptable range and comparable to other routinely
performed nuclear examinations. In comparison, in
humans, the effective dose for 99mTc-annexin V has been
found to be 11 μSv/MBq [25].
51Cr-EDTA was used as a reference substance in order
to calculate renal plasma flow to determine renal clea-
rance of 99mTc-lactadherin and 99mTc-annexinV. We
found a 51Cr-EDTA renal extraction of 21.6%, which is in
concordance with earlier studies in pigs. During the
experiment, the renal extraction of 51Cr-EDTA decreasedslightly. Unlike humans, pigs have several kidney veins,
which are both smaller and shorter than in humans. This
makes blood sampling from the renal vein difficult. The
concentration of 51Cr-EDTA is higher in the caval
vein than in the renal veins, and contamination with
caval blood would lead to an underestimation of the
renal 51Cr-EDTA extraction. Contamination with
blood from the inferior caval vein might explain the
observed drop in EDTA excretion.
51Cr-EDTA is known to be excreted solely in the
urine. The discrepancy between the plasma and uri-
nary clearance of 51Cr-EDTA represents a bias that
can be caused by the different methods used to esti-
mate the two clearances.
The initial renal extraction fraction of 99mTc-annexin
V was more than 10% (Figure 3) but decreased to zero
during the first 2 h of the experiment. Consequently, the
contribution of the kidneys to the total plasma clearance
decreased during the study period. On average, the renal
extraction fraction of 99mTc-annexin V was 3.7%.
The renal extraction fraction of 99mTc-lactadherin was
very close to zero throughout the study period. The
amount of 99mTc-lactadherin cleared from the blood on
its way through the kidney was therefore very small. We
found that the urinary clearance of 99mTc-lactadherin
exceeded the renal clearance. This has to be explained from
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measurement.
Overall, the results from the present tracer kinetic study
in pigs were in accordance with the findings of recent
studies in mice and humans [21,25]. Choosing a pig
model was motivated by the knowledge of its genetic
and physiological similarities to humans.
Further studies of the hepatic metabolism of 99mTc-
lactadherin are necessary to ensure a full understanding
of the kinetic and biodistribution of the tracer. Moreover,
it would be highly relevant to study 99mTc-lactadherin's
ability to visualise PS externalisation in apoptosis,
ischemic or inflammatory experimental models.
Finally, an adequate patient dosimetry study of 99mTc-
lactadherin is recommended before a potential clinical
imaging with 99mTc-lactadherin.
Conclusions
The high hepatic uptake of 99mTc-lactadherin may com-
promise the use of 99mTc-lactadherin for visualisation of PS
externalisation in the liver and in organs close to the liver.
In contrast to 99mTc-annexin, 99mTc-lactadherin has a low
renal uptake and may be the preferred tracer for imaging
PS externalisation in the kidneys. The biodistribution of
99mTc-annexin V favours this tracer as the preferred marker
for imaging PS externalisation in the upper abdomen and
the lower thorax.
The estimated effective human dose after a single in-
jection of 99mTc-lactadherin is in the clinically acceptable
range and comparable to other routinely performed nu-
clear examinations. However, recommendation regarding
the clinical use of 99mTc-lactadherin must await tracer
kinetic studies and dosimetry calculations in patients.
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